Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Lesion dimensions following ablative fractional laser treatment in non-melanoma skin cancer and premalignant lesions

Lesion dimensions following ablative fractional laser treatment in non-melanoma skin cancer and... Lasers Med Sci (2012) 27:675–679 DOI 10.1007/s10103-011-0997-8 BRIEF REPORT Lesion dimensions following ablative fractional laser treatment in non-melanoma skin cancer and premalignant lesions Katrine Togsverd-Bo & Uwe Paasch & Christina S. Haak & Merete Haedersdal Received: 18 August 2011 /Accepted: 12 September 2011 /Published online: 1 October 2011 Springer-Verlag London Ltd 2011 Introduction (Er:YAG, 2,940 nm) and yttrium scandium gallium garnet lasers (YSGG, 2,790 nm), all of which have a high Non-melanoma skin cancer (NMSC), which comprises absorption in the target chromophore, water, and thus basal cell carcinomas (BCC) and squamous cell carcinomas target intra- and extracellular water-rich components such (SCC), is the most common human cancer with an as keratinocytes and vessels [6]. AFXL resurfacing is estimated incidence of more than one million new cancers currently used in the treatment of photodamaged skin, per year alone in the USA [1–5]. SCC may be preceded by wrinkles, and acne and burn scars, but so far not for precursor lesions such as actinic keratoses (AK) and SCC in malignant or premalignant lesions, which is the case for situ (Bowen’s disease), whereas BCCs are regarded as conventional ablative lasers [9–13]. invasive tumours from the beginning. The incidence of the Theimmediatetissuedamageafter AFXL http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Lasers in Medical Science Springer Journals

Lesion dimensions following ablative fractional laser treatment in non-melanoma skin cancer and premalignant lesions

Loading next page...
 
/lp/springer-journals/lesion-dimensions-following-ablative-fractional-laser-treatment-in-non-xWsoWhmBFL

References (22)

Publisher
Springer Journals
Copyright
Copyright © 2011 by Springer-Verlag London Ltd
Subject
Medicine & Public Health; Optics, Optoelectronics, Plasmonics and Optical Devices; Medicine/Public Health, general; Quantum Optics; Laser Technology, Photonics; Dentistry
ISSN
0268-8921
eISSN
1435-604X
DOI
10.1007/s10103-011-0997-8
pmid
21960122
Publisher site
See Article on Publisher Site

Abstract

Lasers Med Sci (2012) 27:675–679 DOI 10.1007/s10103-011-0997-8 BRIEF REPORT Lesion dimensions following ablative fractional laser treatment in non-melanoma skin cancer and premalignant lesions Katrine Togsverd-Bo & Uwe Paasch & Christina S. Haak & Merete Haedersdal Received: 18 August 2011 /Accepted: 12 September 2011 /Published online: 1 October 2011 Springer-Verlag London Ltd 2011 Introduction (Er:YAG, 2,940 nm) and yttrium scandium gallium garnet lasers (YSGG, 2,790 nm), all of which have a high Non-melanoma skin cancer (NMSC), which comprises absorption in the target chromophore, water, and thus basal cell carcinomas (BCC) and squamous cell carcinomas target intra- and extracellular water-rich components such (SCC), is the most common human cancer with an as keratinocytes and vessels [6]. AFXL resurfacing is estimated incidence of more than one million new cancers currently used in the treatment of photodamaged skin, per year alone in the USA [1–5]. SCC may be preceded by wrinkles, and acne and burn scars, but so far not for precursor lesions such as actinic keratoses (AK) and SCC in malignant or premalignant lesions, which is the case for situ (Bowen’s disease), whereas BCCs are regarded as conventional ablative lasers [9–13]. invasive tumours from the beginning. The incidence of the Theimmediatetissuedamageafter AFXL

Journal

Lasers in Medical ScienceSpringer Journals

Published: Oct 1, 2011

There are no references for this article.